NASDAQ:ILMN

Illumina Stock Forecast, Price & News

$418.28

-2.72 (-0.65 %)

(As of 01/26/2021 03:46 PM ET)

Add

Compare

Today's Range

$416.38

Now: $418.28▼

$425.19

50-Day Range

$337.76

MA: $369.09▼

$406.25

52-Week Range

$196.78

Now: $418.28▼

$425.71

Volume31,883 shs

Average Volume1.21 million shs

Market Capitalization$61.07 billion

P/E Ratio97.05

Dividend YieldN/A

Beta1.14

Illumina, Inc. provides sequencing and array-based solutions for genetic and genomic analysis. Its products and services serve customers in a range of markets enabling the adoption of genomic solutions in research and clinical settings for applications in the life sciences, oncology, reproductive health, agriculture and other emerging segments. The company provides instruments and consumables used in genetic analysis; and genotyping and sequencing services, instrument service contracts, and development and licensing agreements. Its customers include genomic research centers, academic institutions, government laboratories, and hospitals, as well as pharmaceutical, biotechnology, commercial molecular diagnostic laboratories, and consumer genomics companies. The company markets and distributes its products directly to customers in North America, Europe, Latin America, and the Asia-Pacific region, as well as sells through life-science distributors in certain markets within Europe, the Asia-Pacific region, Latin America, the Middle East, and Africa. Illumina, Inc. was founded in 1998 and is headquartered in San Diego, California.

MarketRank^™

Overall MarketRank^™

1.45 out of 5 stars

Medical Sector

473rd out of 1,925 stocks

Analytical Instruments Industry

9th out of 29 stocks

1.1 Analyst's Opinion

Consensus Rating
Illumina has received a consensus rating of Hold. The company's average rating score is 2.26, and is based on 8 buy ratings, 8 hold ratings, and 3 sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $333.30, Illumina has a forecasted downside of 20.3% from its current price of $418.28.
Amount of Analyst Coverage
Illumina has only been the subject of 4 research reports in the past 90 days.

2.6 Community Rank

Outperform Votes
Illumina has received 1,026 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
Illumina has received 921 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
Illumina has received 52.70% “outperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about Illumina and other stocks. Vote “Outperform” if you believe ILMN will outperform the S&P 500 over the long term. Vote “Underperform” if you believe ILMN will underperform the S&P 500 over the long term. You may vote once every thirty days.

0.0 Dividend Strength

Dividend Yield
Illumina does not currently pay a dividend.
Dividend Growth
Illumina does not have a long track record of dividend growth.

1.7 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Illumina insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $12,648,560.00 in company stock.
Percentage Held by Insiders
Only 0.38% of the stock of Illumina is held by insiders.
Percentage Held by Institutions
89.97% of the stock of Illumina is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

1.9 Earnings and Valuation

Earnings Growth
Earnings for Illumina are expected to grow by 19.13% in the coming year, from $4.39 to $5.23 per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Illumina is 97.05, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 24.13.
Price to Earnings Ratio vs. Sector
The P/E ratio of Illumina is 97.05, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 37.08.
Price to Earnings Growth Ratio
Illumina has a PEG Ratio of 9.83. PEG Ratios above 1 indicate that a company could be overvalued.
Price to Book Value per Share Ratio
Illumina has a P/B Ratio of 13.33. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Industry, Sector and Symbol

Stock Exchange NASDAQ

Industry Analytical instruments

Sub-IndustryLife Sciences Tools & Services

SectorMedical

Current SymbolNASDAQ:ILMN

Previous Symbol

CUSIP45232710

CIK1110803

Webwww.illumina.com

Phone858-202-4500

Employees7,700

Year FoundedN/A

Debt

Debt-to-Equity Ratio0.14

Current Ratio3.88

Quick Ratio3.51

Price-To-Earnings

Trailing P/E Ratio97.05

Forward P/E Ratio95.28

P/E Growth9.83

Sales & Book Value

Annual Sales$3.54 billion

Price / Sales17.24

Cash Flow$9.51 per share

Price / Cash Flow43.98

Book Value$31.38 per share

Price / Book13.33

Profitability

EPS (Most Recent Fiscal Year)$6.57

Net Income$1.00 billion

Net Margins19.70%

Return on Equity15.93%

Return on Assets10.09%

Miscellaneous

Outstanding Shares146,000,000

Market Cap$61.07 billion

Next Earnings Date2/3/2021 (Estimated)

OptionableOptionable

$418.28

-2.72 (-0.65 %)

(As of 01/26/2021 03:46 PM ET)

30 days | 90 days | 365 days | Advanced Chart

Receive ILMN News and Ratings via Email

Sign-up to receive the latest news and ratings for ILMN and its competitors with MarketBeat's FREE daily newsletter.

Illumina (NASDAQ:ILMN) Frequently Asked Questions

How has Illumina's stock price been impacted by Coronavirus (COVID-19)?

Illumina's stock was trading at $246.01 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, ILMN stock has increased by 70.0% and is now trading at $418.28.
View which stocks have been most impacted by COVID-19.

Is Illumina a buy right now?

19 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Illumina in the last twelve months. There are currently 3 sell ratings, 8 hold ratings and 8 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" Illumina stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ILMN, but not buy additional shares or sell existing shares.
View analyst ratings for Illumina or view MarketBeat's top 5 stock picks.

What stocks does MarketBeat like better than Illumina?

Wall Street analysts have given Illumina a "Hold" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Illumina wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

What is Francis deSouza's approval rating as Illumina's CEO?

496 employees have rated Illumina CEO Francis deSouza on Glassdoor.com. Francis deSouza has an approval rating of 92% among Illumina's employees. This puts Francis deSouza in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

When is Illumina's next earnings date?

Illumina is scheduled to release its next quarterly earnings announcement on Wednesday, February 3rd 2021.
View our earnings forecast for Illumina.

How were Illumina's earnings last quarter?

Illumina, Inc. (NASDAQ:ILMN) announced its earnings results on Thursday, October, 29th. The life sciences company reported $1.02 earnings per share for the quarter, topping analysts' consensus estimates of $0.77 by $0.25. The life sciences company earned $794 million during the quarter, compared to analyst estimates of $713.97 million. Illumina had a trailing twelve-month return on equity of 15.93% and a net margin of 19.70%. Illumina's quarterly revenue was down 12.5% compared to the same quarter last year. During the same quarter in the previous year, the company earned $1.93 earnings per share.
View Illumina's earnings history.

What price target have analysts set for ILMN?

19 brokerages have issued twelve-month target prices for Illumina's stock. Their forecasts range from $280.00 to $415.00. On average, they anticipate Illumina's share price to reach $333.30 in the next twelve months. This suggests that the stock has a possible downside of 20.3%.
View analysts' price targets for Illumina or view Wall Street analyst' top-rated stocks.

Who are some of Illumina's key competitors?

Some companies that are related to Illumina include Thermo Fisher Scientific (TMO), Agilent Technologies (A), Mettler-Toledo International (MTD), Bio-Rad Laboratories (BIO), Waters (WAT), PerkinElmer (PKI), Bio-Techne (TECH), Charles River Laboratories International (CRL), Bruker (BRKR), Pacific Biosciences of California (PACB), Luminex (LMNX), Fluidigm (FLDM), Harvard Bioscience (HBIO), aTyr Pharma (LIFE) and BG Medicine (BGMD).
View all of ILMN's competitors.

What other stocks do shareholders of Illumina own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Illumina investors own include NVIDIA (NVDA), Alibaba Group (BABA), Tesla (TSLA), Netflix (NFLX), The Walt Disney (DIS), PayPal (PYPL), salesforce.com (CRM), Adobe (ADBE), Visa (V) and Micron Technology (MU).

Who are Illumina's key executives?

Illumina's management team includes the following people:

Mr. Francis A. deSouza, CEO, Pres & Director (Age 49)
Mr. Sam A. Samad, CFO & Sr. VP (Age 50, Pay $626.7k)
Dr. Joydeep Goswami, Sr. VP of Corp. Devel. & Strategic Planning (Age 49, Pay $384.38k)
Ms. Aimee L. Hoyt, Chief People Officer & Sr. VP (Age 49, Pay $864.07k)
Mr. Robert P. Ragusa, Sr. VP of Global Quality & Operations (Age 60)
Ms. Karen K. McGinnis, VP & Chief Accounting Officer (Age 53)
Dr. Alexander Aravanis M.D., Ph.D., Sr. VP & Chief Technology Officer
Mr. Steve Phillpott, Sr. VP & Chief Information Officer
Ms. Juliet Cunningham, VP of Investor Relations
Mr. Charles E. Dadswell, Sr. VP, Gen. Counsel & Sec. (Age 61)

What is Illumina's stock symbol?

Illumina trades on the NASDAQ under the ticker symbol "ILMN."

Who are Illumina's major shareholders?

Illumina's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Douglas Lane & Associates LLC (0.23%), Sarasin & Partners LLP (0.13%), KAMES CAPITAL plc (0.13%), New York State Teachers Retirement System (0.12%), Ardevora Asset Management LLP (0.10%) and DAVENPORT & Co LLC (0.10%). Company insiders that own Illumina stock include Aimee L Hoyt, Charles Dadswell, Frances Arnold, Francis A Desouza, Jay T Flatley, Karen K Mcginnis, Mostafa Ronaghi, Oene Mark Van, Omead Ostadan, Phillip G Febbo, Robert P Ragusa, Robert S Epstein, Sam Samad and Susan H Tousi.
View institutional ownership trends for Illumina.

Which major investors are selling Illumina stock?

ILMN stock was sold by a variety of institutional investors in the last quarter, including Frontier Capital Management Co. LLC, Waverton Investment Management Ltd, Gateway Investment Advisers LLC, Pacer Advisors Inc., New York State Teachers Retirement System, Douglas Lane & Associates LLC, Nisa Investment Advisors LLC, and Chicago Capital LLC. Company insiders that have sold Illumina company stock in the last year include Aimee L Hoyt, Charles Dadswell, Frances Arnold, Francis A Desouza, Jay T Flatley, Karen K Mcginnis, Mostafa Ronaghi, Oene Mark Van, Phillip G Febbo, Robert P Ragusa, Sam Samad, and Susan H Tousi.
View insider buying and selling activity for Illumina or view top insider-selling stocks.

Which major investors are buying Illumina stock?

ILMN stock was bought by a variety of institutional investors in the last quarter, including Ardevora Asset Management LLP, Retirement Systems of Alabama, Private Capital Advisors Inc., Sarasin & Partners LLP, KAMES CAPITAL plc, Kestra Advisory Services LLC, Louisiana State Employees Retirement System, and YorkBridge Wealth Partners LLC.
View insider buying and selling activity for Illumina or or view top insider-buying stocks.

How do I buy shares of Illumina?

Shares of ILMN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Illumina's stock price today?

One share of ILMN stock can currently be purchased for approximately $418.28.

How big of a company is Illumina?

Illumina has a market capitalization of $61.07 billion and generates $3.54 billion in revenue each year. The life sciences company earns $1.00 billion in net income (profit) each year or $6.57 on an earnings per share basis. Illumina employs 7,700 workers across the globe.

What is Illumina's official website?

The official website for Illumina is www.illumina.com.

How can I contact Illumina?

Illumina's mailing address is 200 ILLUMINA WAY, SAN DIEGO CA, 92122. The life sciences company can be reached via phone at 858-202-4500 or via email at [email protected]

This page was last updated on 1/26/2021 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here